FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208762068> ?p ?o ?g. }

• W3208762068 abstract "Tumor glycolysis is a target for cancer chemotherapy. Methylglyoxal (MG) is a reactive metabolite formed mainly as a by-product in anaerobic glycolysis, metabolized by glyoxalase 1 (Glo1) of the glyoxalase system. We investigated the role of MG and Glo1 in cancer chemotherapy related in multidrug resistance (MDR).Human Glo1 was overexpressed in HEK293 cells and the effect on anticancer drug potency, drug-induced increase in MG and mechanism of cytotoxicity characterized. Drug-induced increased MG and the mechanisms driving it were investigated and the proteomic response to MG-induced cytotoxicity explored by high mass resolution proteomics of cytoplasmic and other subcellular protein extracts. Glo1 expression data of 1,040 human tumor cell lines and 7,489 tumors were examined for functional correlates and impact of cancer patient survival.Overexpression of Glo1 decreased cytotoxicity of antitumor drugs, impairing antiproliferative activity of alkylating agents, topoisomerase inhibitors, antitubulins, and antimetabolites. Antitumor drugs increased MG to cytotoxic levels which contributed to the cytotoxic, antiproliferative mechanism of action, consistent with Glo1-mediated MDR. This was linked to off-target effects of drugs on glycolysis and was potentiated in hypoxia. MG activated the intrinsic pathway of apoptosis, with decrease of mitochondrial and spliceosomal proteins. Spliceosomal proteins were targets of MG modification. Spliceosomal gene expression correlated positively with Glo1 in human tumor cell lines and tumors. In clinical chemotherapy of breast cancer, increased expression of Glo1 was associated with decreased patient survival, with hazard ratio (HR) = 1.82 (logrank p < 0.001, n = 683) where upper quartile survival of patients was decreased by 64% with high Glo1 expression.We conclude that MG-mediated cytotoxicity contributes to the cancer chemotherapeutic response and targets the spliceosome. High expression of Glo1 contributes to multidrug resistance by shielding the spliceosome from MG modification and decreasing survival in the chemotherapy of breast cancer. Adjunct chemotherapy with Glo1 inhibitor may improve treatment outcomes." @default.
• W3208762068 created "2021-11-08" @default.
• W3208762068 creator A5014507517 @default.
• W3208762068 creator A5021086938 @default.
• W3208762068 creator A5050285244 @default.
• W3208762068 creator A5050633955 @default.
• W3208762068 creator A5075275944 @default.
• W3208762068 creator A5091085661 @default.
• W3208762068 date "2021-11-01" @default.
• W3208762068 modified "2023-09-30" @default.
• W3208762068 title "Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome" @default.
• W3208762068 cites W1487088539 @default.
• W3208762068 cites W1921881567 @default.
• W3208762068 cites W1972681776 @default.
• W3208762068 cites W1974900771 @default.
• W3208762068 cites W1989745235 @default.
• W3208762068 cites W1990310347 @default.
• W3208762068 cites W1992981136 @default.
• W3208762068 cites W1999891632 @default.
• W3208762068 cites W2015556811 @default.
• W3208762068 cites W2022173379 @default.
• W3208762068 cites W2024310939 @default.
• W3208762068 cites W2024667408 @default.
• W3208762068 cites W2028308601 @default.
• W3208762068 cites W2029423207 @default.
• W3208762068 cites W2039231543 @default.
• W3208762068 cites W2042619042 @default.
• W3208762068 cites W2068274700 @default.
• W3208762068 cites W2074651846 @default.
• W3208762068 cites W2075627538 @default.
• W3208762068 cites W2076972400 @default.
• W3208762068 cites W2079903385 @default.
• W3208762068 cites W2085934079 @default.
• W3208762068 cites W2086879967 @default.
• W3208762068 cites W2089573675 @default.
• W3208762068 cites W2121056634 @default.
• W3208762068 cites W2125789330 @default.
• W3208762068 cites W2148555906 @default.
• W3208762068 cites W2150381945 @default.
• W3208762068 cites W2152366277 @default.
• W3208762068 cites W2158217645 @default.
• W3208762068 cites W2168418835 @default.
• W3208762068 cites W2170597525 @default.
• W3208762068 cites W2235575941 @default.
• W3208762068 cites W2309067861 @default.
• W3208762068 cites W2398262997 @default.
• W3208762068 cites W2414165404 @default.
• W3208762068 cites W2470810595 @default.
• W3208762068 cites W2522437666 @default.
• W3208762068 cites W2612102113 @default.
• W3208762068 cites W2758067903 @default.
• W3208762068 cites W2889646458 @default.
• W3208762068 cites W2899130161 @default.
• W3208762068 cites W2901671835 @default.
• W3208762068 cites W2938150871 @default.
• W3208762068 cites W2944896292 @default.
• W3208762068 cites W2946452982 @default.
• W3208762068 cites W3044890580 @default.
• W3208762068 cites W3087564775 @default.
• W3208762068 cites W3095820202 @default.
• W3208762068 cites W3103159418 @default.
• W3208762068 cites W3139511935 @default.
• W3208762068 cites W4210267679 @default.
• W3208762068 cites W5795953 @default.
• W3208762068 doi "https://doi.org/10.3389/fonc.2021.748698" @default.
• W3208762068 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8591171" @default.
• W3208762068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34790575" @default.
• W3208762068 hasPublicationYear "2021" @default.
• W3208762068 type Work @default.
• W3208762068 sameAs 3208762068 @default.
• W3208762068 citedByCount "8" @default.
• W3208762068 countsByYear W32087620682022 @default.
• W3208762068 countsByYear W32087620682023 @default.
• W3208762068 crossrefType "journal-article" @default.
• W3208762068 hasAuthorship W3208762068A5014507517 @default.
• W3208762068 hasAuthorship W3208762068A5021086938 @default.
• W3208762068 hasAuthorship W3208762068A5050285244 @default.
• W3208762068 hasAuthorship W3208762068A5050633955 @default.
• W3208762068 hasAuthorship W3208762068A5075275944 @default.
• W3208762068 hasAuthorship W3208762068A5091085661 @default.
• W3208762068 hasBestOaLocation W32087620681 @default.
• W3208762068 hasConcept C109316439 @default.
• W3208762068 hasConcept C121608353 @default.
• W3208762068 hasConcept C133936738 @default.
• W3208762068 hasConcept C181199279 @default.
• W3208762068 hasConcept C185592680 @default.
• W3208762068 hasConcept C202751555 @default.
• W3208762068 hasConcept C2778592357 @default.
• W3208762068 hasConcept C501593827 @default.
• W3208762068 hasConcept C502942594 @default.
• W3208762068 hasConcept C54355233 @default.
• W3208762068 hasConcept C55493867 @default.
• W3208762068 hasConcept C86803240 @default.
• W3208762068 hasConcept C96232424 @default.
• W3208762068 hasConcept C98274493 @default.
• W3208762068 hasConceptScore W3208762068C109316439 @default.
• W3208762068 hasConceptScore W3208762068C121608353 @default.
• W3208762068 hasConceptScore W3208762068C133936738 @default.
• W3208762068 hasConceptScore W3208762068C181199279 @default.
• W3208762068 hasConceptScore W3208762068C185592680 @default.

• next